Drug intelligence / Profile preview

LR02

Development stage: Discontinued
Lead developer: Laevoroc Oncology
Modality: Small Molecules
Administration: Oral

Overview

LR02 is an investigational **small-molecule ATR inhibitor** developed by Laevoroc Oncology. It is described as a serine-protein kinase ATR inhibitor designed to block ataxia telangiectasia and Rad3-related protein signaling, a key component of the DNA damage response, with intended applications in **neoplasms** and potentially **nervous system diseases**. Based on the provided context, LR02 did not reach approval and its highest global research and development status is **discontinued**.

Targets

ATR (ATR serine/threonine kinase)

Beyond the preview

Go deeper on LR02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LR02.

Explore the full profile